Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MJT.0000000000001131 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical sirolimus in dermatology: a systematic review.
Clin Exp Dermatol
December 2024
Mid Cheshire NHS Foundation Trust, Crewe, UK.
Topical sirolimus is increasingly utilized off-licence to manage various dermatological conditions while avoiding typical adverse effects associated with systemic sirolimus. However, widespread use is limited by a highly heterogeneous evidence base of mixed quality. Our aim was to evaluate the current evidence base for the indications, efficacy and safety profile of topical sirolimus in dermatology.
View Article and Find Full Text PDFEverolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
Int J Mol Sci
December 2023
Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Hepatocellular carcinoma (HCC) is a challenging cancer to treat, as traditional chemotherapies have shown limited effectiveness. The mammalian target of rapamycin/sirolimus (mTOR) and microtubules are prominent druggable targets for HCC. In this study, we demonstrated that co-targeting mTOR using mTOR inhibitors (everolimus and sirolimus) along with the microtubule inhibitor vinorelbine yielded results superior to those of the monotherapies in HCC PDX models.
View Article and Find Full Text PDFWhy Is Rapamycin Not a Rapalog?
Gerontology
June 2023
Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug Administration (FDA). It is also a leading candidate for targeting aging. Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins (FKBP) and have a similar chemical structure that only differs in the functional group present at carbon-40.
View Article and Find Full Text PDFUse of mTOR inhibitors (rapalogs) for the treatment of skin changes in tuberous sclerosis complex.
Arch Pediatr
December 2022
Service de Dermatologie, CHU d'Angers, 49000 Angers, France; CRMR MAGEC Nord, CHU d'Angers, 49000 Angers, France. Electronic address:
Background: Skin manifestations of Tuberous Sclerosis Complex (TSC) are present in more than 90% of patients. Facial angiofibromas (AF) are considered a skin hallmark of TSC. They are responsible for esthetic impact in patients.
View Article and Find Full Text PDFTranslation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group.
Front Immunol
November 2022
Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, United States.
Background: Immunocompromised (IC) patients show diminished immune response to COVID-19 mRNA vaccines (Co-mV). To date, there is no 'empirical' evidence to link the perturbation of translation, a rate-limiting step for mRNA vaccine efficiency (VE), to the dampened response of Co-mV.
Materials And Methods: Impact of immunosuppressants (ISs), tacrolimus (T), mycophenolate (M), rapamycin/sirolimus (S), and their combinations on Pfizer Co-mV translation were determined by the Spike (Sp) protein expression following Co-mV transfection in HEK293 cells.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!